Innate Immunity and Neurodegeneration

Annual Review of Medicine

Volumn 69, Issue , 2018, Pages 437-449

  Labzin, Larisa I ^a   Heneka, Michael T ^b,d,e   Latz, Eicke ^c,d,e,f  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b University Clinics   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^f NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease; Inflammasomes; Neuroinflammation; Parkinson's disease; Toll like receptors

Indexed keywords

PATTERN RECOGNITION RECEPTOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CELL ACTIVATION; CELL FUNCTION; DEGENERATIVE DISEASE; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; INNATE IMMUNITY; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; IMMUNOLOGY; INFLAMMATION;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; HUMANS; HUNTINGTON DISEASE; IMMUNITY, INNATE; INFLAMMATION; MICROGLIA; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 85041724931     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-050715-104343     Document Type: Article

References (81)

1. Dugger BN, Dickson DW. 2017. Pathology of neurodegenerative diseases. Cold Spring Harb. Perspect. Biol. 9(7):a028035
2. Goedert M, Masuda-Suzukake M, Falcon B. 2017. Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration. Brain 140:266-78
3. Selkoe DJ, Hardy J. 2016. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 8(6):595-608
4. Wyss-Coray T. 2016. Ageing, neurodegeneration and brain rejuvenation. Nature 539(7628):180-86
5. Martin P, Wimo A, Guerchet M, et al. 2015. World Alzheimer report 2015: the global impact of dementia. Alzheimer's Disease Int. (ADI), London. http://www.alz.co.uk/worldreport2015
6. Masters CL, Bateman R, Blennow K, et al. 2015. Alzheimer's disease. Nat. Rev. Dis. Primers 1:15056
7. Massano J, Bhatia KP. 2012. Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. Cold Spring Harb. Perspect. Med. 2(6):a008870-70
8. Kalia LV, Lang AE. 2015. Parkinson's disease. Lancet 386(9996):896-912
9. Sibilla C, Bertolotti A. 2017. Prion properties of SOD1 in amyotrophic lateral sclerosis and potential therapy. Cold Spring Harb. Perspect. Biol. 9(10):a024141
10. Bates GP, Dorsey R, Gusella JF, et al. 2015. Huntington disease. Nat. Rev. Dis. Primers 1:15005
11. Waisman A, Ginhoux F, Greter M, Bruttger J. 2015. Homeostasis of microglia in the adult brain: review of novel microglia depletion systems. Trends Immunol. 36(10):625-36
12. Lavin Y,Winter D, Blecher-Gonen R, et al. 2014. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159(6):1312-26
13. Ginhoux F, Greter M, Leboeuf M, et al. 2010. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330(6005):841-45
14. Ajami B, Bennett JL, Krieger C, et al. 2007. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 10(12):1538-43
15. Stevens B, Allen NJ, Vazquez LE, et al. 2007. The classical complement cascade mediates CNS synapse elimination. Cell 131(6):1164-78
16. Paolicelli RC, Bolasco G, Pagani F, et al. 2011. Synaptic pruning by microglia is necessary for normal brain development. Science 333(6048):1456-58
17. Fourgeaud L, Través PG, Tufail Y, et al. 2016. TAM receptors regulate multiple features of microglial physiology. Nature 532 (7598):240-44
18. Parkhurst CN, Yang G, Ninan I, et al. 2013. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 155(7):1596-609
19. Colonna M, Butovsky O. 2017. Microglia function in the central nervous system during health and neurodegeneration. Annu. Rev. Immunol. 35:441-68
20. Srinivasan K, Friedman BA, Larson JL, et al. 2016. Untangling the brain's neuroinflammatory and neurodegenerative transcriptional responses. Nat. Commun. 7:11295
21. Heneka MT, Kummer MP, Latz E. 2014. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 14(7):463-77
22. Crotti A, Glass CK. 2015. The choreography of neuroinflammation in Huntington's disease. Trends Immunol. 36(6):364-73
23. Davalos D, Grutzendler J, Yang G, et al. 2005. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8(6):752-58
24. Freeman L, Guo H, David CN, et al. 2017. NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes. J. Exp. Med. 214(5):1351-70
25. Kigerl KA, de Rivero Vaccari JP, Dietrich WD, et al. 2014. Pattern recognition receptors and central nervous system repair. Exp. Neurol. 258:5-16
26. De Nardo D. 2015. Toll-like receptors: activation, signalling and transcriptional modulation. Cytokine 74(2):181-89
27. Latz E, Xiao TS, Stutz A. 2013. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13(6):397-411
28. Cox DJ, Field RH, Williams DG, et al. 2015. DNA sensors are expressed in astrocytes and microglia in vitro and are upregulated during gliosis in neurodegenerative disease. Glia 63(5):812-25
29. Yan SD, Chen X, Fu J, et al. 1996. RAGE and amyloid-βpeptide neurotoxicity in Alzheimer's disease. Nature 382(6593):685-91
30. Deane R, Singh I, Sagare AP, et al. 2012. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Investig. 122(4):1377-92
31. El Khoury JB, MooreKJ, MeansTK, et al. 2003. CD36 mediates the innate host response to beta-amyloid. J. Exp. Med. 197(12):1657-66
32. Stewart CR, Stuart LM, Wilkinson K, et al. 2010. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 11(2):155-61
33. Sheedy FJ, Grebe A, Rayner KJ, et al. 2013. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat. Immunol. 14(8):812-20
34. Halle A, Hornung V, Petzold GC, et al. 2008. The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat. Immunol. 9(8):857-65
35. Heneka MT,KummerMP, Stutz A, et al. 2013. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493(7434):674-78
36. Saresella M, La Rosa F, Piancone F, et al. 2016. The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease. Mol. Neurodegener. 11:23-17
37. Dempsey C, Rubio Araiz A, Bryson KJ, et al. 2017. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-βand cognitive function in APP/PS1 mice. Brain Behav. Immun. 61:306-16
38. Tan M-S, Tan L, Jiang T, et al. 2014. Amyloid-β induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer's disease. Cell Death Disease 5(8):e1382-12
39. Kaushal V, DyeR, Pakavathkumar P, et al. 2015. Neuronal NLRP1 inflammasome activation of Caspase-1 co-ordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ. 22(10):1676-86
40. Shaftel SS, Griffin WST, O'Banion MK. 2008. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J. Neuroinflamm. 5:7
41. Adamczak SE, de Rivero Vaccari JP, Dale G, et al. 2014. Pyroptotic neuronal cell death mediated by the AIM2 inflammasome. J. Cereb. Blood Flow Metab. 34(4):621-29
42. Denes A, Coutts G, Lénárt N, et al. 2015. AIM2 and NLRC4 inflammasomes contribute with ASC to acute brain injury independently of NLRP3. PNAS 112(13):4050-55
43. Kim C, Ho D-H, Suk J-E, et al. 2013. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 4:1562-12
44. Daniele SG, Beraud D, Davenport C, et al. 2015. Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders. Sci. Signal. 8(376):ra45
45. Gustot A, Gallea JI, Sarroukh R, et al. 2015. Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease. Biochem. J. 471(3):323-33
46. Fellner L, Irschick R, Schanda K, et al. 2012. Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia 61(3):349-60
47. Noelker C, Morel L, Lescot T, et al. 2013. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci. Rep. 3:1393
48. Codolo G, Plotegher N, Pozzobon T, et al. 2013. Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies. PLOS ONE 8(1):e55375-12 www.annualreviews.org Innate Immunity and Neurodegeneration 447
49. Gustin A, Kirchmeyer M, Koncina E, Felten P. 2015. NLRP3 inflammasome is expressed and functional in mouse brain microglia but not in astrocytes. PLOS ONE 10(6):e0130624
50. Zhou Y, Lu M, Du R-H, et al. 2016. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease. Mol. Neurodegener. 11:28-43
51. Yan Y, Jiang W, Liu L, et al. 2015. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 160(1-2):62-73
52. Zhao W, Beers DR, Bell S, et al. 2015. TDP-43 activates microglia through NF-κB and NLRP3 inflammasome. Exp. Neurol. 273:24-35
53. Meissner F, Molawi K, Zychlinsky A. 2010. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. PNAS 107(29):13046-50
54. Maier A, Deigendesch N, Müller K, et al. 2015. Interleukin-1 antagonist anakinra in amyotrophic lateral sclerosis-A pilot study. PLOS ONE 10(10):e0139684
55. Crotti A, BennerC,KermanBE, et al. 2014. Mutant huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat. Neurosci. 17(4):513-21
56. ZilkaN, Kazmerova Z, Jadhav S, et al. 2012. Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J. Neuroinflamm. 9:47-58
57. BlockML, Zecca L, Hong J-S. 2007. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8(1):57-69
58. Heneka MT, Carson MJ, Khoury El J, et al. 2015. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 14(4):388-405
59. Guillot-Sestier M-V, Doty KR, Town T. 2015. Innate immunity fights Alzheimer's disease. Trends Neurosci. 38(11):674-81
60. Hickman SE, Allison EK, El Khoury J. 2008. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 28(33):8354-60
61. Hong S, Beja-Glasser VF, Nfonoyim BM, et al. 2016. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352(6286):712-16
62. Colonna M, Wang Y. 2016. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat. Rev. Neurosci. 17(4):201-7
63. Turnbull IR, Gilfillan S, Cella M, et al. 2006. Cutting edge: TREM-2 attenuates macrophage activation. J. Immunol. 177(6):3520-24
64. Hamerman JA, Jarjoura JR, Humphrey MB, et al. 2006. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J. Immunol. 177(4):2051-55
65. Bin Zhang, Gaiteri C, Bodea L-G, et al. 2013. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 153(3):707-20
66. Jiang T, Tan L, Zhu X-C, et al. 2014. Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mousemodel of Alzheimer's disease. Neuropsychopharmacology 39(13):2949-62
67. Jay TR, Miller CM, Cheng PJ, et al. 2015. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mousemodels. J. Exp. Med. 212(3):287-95
68. Wang Y, Cella M, Mallinson K, et al. 2015. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160(6):1061-71
69. Condello C, Yuan P, Schain A, Grutzendler J. 2015. Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques. Nat. Commun. 6:6176-28
70. Atagi Y, Liu C-C, Painter MM, et al. 2015. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J. Biol. Chem. 290(43):26043-50
71. Bailey CC, DeVaux LB, Farzan M. 2015. The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J. Biol. Chem. 290(43):26033-42
72. Mosher KI,Wyss-Coray T. 2014. Microglial dysfunction in brain aging and Alzheimer's disease. Biochem. Pharmacol. 88(4):594-604
73. Perry VH,HolmesC. 2014. Microglial priming in neurodegenerative disease. Nat. Rev.Neurol. 10(4):217-24
74. Netea MG, Joosten LAB, Latz E, et al. 2016. Trained immunity: a program of innate immune memory in health and disease. Science 352(6284):aaf1098-98
75. Tang Y, Li T, Li J, et al. 2014. Jmjd3 is essential for the epigenetic modulation of microglia phenotypes in the immune pathogenesis of Parkinson's disease. Cell Death Differ. 21(3):369-80
76. Gjoneska E, Pfenning AR, Mathys H, et al. 2015. Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer's disease. Nature 518(7539):365-69
77. CunninghamC. 2013. Microglia and neurodegeneration: the role of systemic inflammation. Glia 61(1):71-90
78. Erny D, Hrabě de Angelis AL, Jaitin D, et al. 2015. Host microbiota constantly control maturation and function of microglia in the CNS. Nat. Neurosci. 18(7):965-77
79. Braniste V, Al-Asmakh M, Kowal C, et al. 2014. The gut microbiota influences blood-brain barrier permeability in mice. Sci. Transl. Med. 6(263):ra158-58
80. Lee-Kirsch MA. 2017. The type I interferonopathies. Annu. Rev. Med. 68:297-315
81. Baruch K, Deczkowska A, David E, et al. 2014. Aging. Aging-induced type I interferon response at the choroid plexus negatively affects brain function. Science 346(6205):89-93